RU2014140792A - Активированная иммуностимулирующая клеточная композиция и ее использование - Google Patents

Активированная иммуностимулирующая клеточная композиция и ее использование Download PDF

Info

Publication number
RU2014140792A
RU2014140792A RU2014140792A RU2014140792A RU2014140792A RU 2014140792 A RU2014140792 A RU 2014140792A RU 2014140792 A RU2014140792 A RU 2014140792A RU 2014140792 A RU2014140792 A RU 2014140792A RU 2014140792 A RU2014140792 A RU 2014140792A
Authority
RU
Russia
Prior art keywords
composition
leukocytes
medium
cells
tumor
Prior art date
Application number
RU2014140792A
Other languages
English (en)
Russian (ru)
Inventor
Ирен Гинис
Алан Смит
Ади ЗУЛОФФ-ШАНИ
Марина БУБИС
Митчелл Ширван
Original Assignee
Макрокьюэ, Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Макрокьюэ, Лтд. filed Critical Макрокьюэ, Лтд.
Publication of RU2014140792A publication Critical patent/RU2014140792A/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4271—Melanoma antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/57—Skin; melanoma
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2521/00—Culture process characterised by the use of hydrostatic pressure, flow or shear forces

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
RU2014140792A 2012-03-15 2013-03-13 Активированная иммуностимулирующая клеточная композиция и ее использование RU2014140792A (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261611202P 2012-03-15 2012-03-15
US61/611,202 2012-03-15
PCT/IB2013/000848 WO2013136182A1 (en) 2012-03-15 2013-03-13 Activated immunostimulatory cell composition and uses thereof

Publications (1)

Publication Number Publication Date
RU2014140792A true RU2014140792A (ru) 2016-05-10

Family

ID=48326349

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2014140792A RU2014140792A (ru) 2012-03-15 2013-03-13 Активированная иммуностимулирующая клеточная композиция и ее использование

Country Status (8)

Country Link
US (1) US20150030635A1 (2)
EP (1) EP2825634A1 (2)
JP (1) JP2015516374A (2)
CA (1) CA2865553A1 (2)
IN (1) IN2014DN08093A (2)
MX (1) MX2014010958A (2)
RU (1) RU2014140792A (2)
WO (1) WO2013136182A1 (2)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103209682A (zh) 2010-09-09 2013-07-17 马克罗柯尔有限公司 活化白血球调节上清液以及用于伤口愈合的用途
WO2016075542A1 (en) * 2014-11-11 2016-05-19 Macrocure, Ltd. Methods for extended storage of activated leukocyte compositions
WO2017040969A1 (en) 2015-09-02 2017-03-09 The Cleveland Clinic Foundation Ovarian cancer vaccines

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7713739B1 (en) 2000-11-17 2010-05-11 Novartis Vaccines And Diagnostics, Inc. Microparticle-based transfection and activation of dendritic cells
US7935531B2 (en) 2000-02-22 2011-05-03 Board Of Trustees Of The University Of Arkansas Methods for the early diagnosis of ovarian cancer
JP2005510491A (ja) * 2001-10-26 2005-04-21 イミュノ−アールエックス， インコーポレイテッド 免疫抑制を逆転させるための免疫治療
EP2181595A1 (en) 2002-08-16 2010-05-05 Yeda Research And Development Company Ltd. Tumor associated antigen, peptides thereof, and use of same as anti-tumor vaccines
KR101131727B1 (ko) 2004-06-11 2012-03-28 가톨릭대학교 산학협력단 ＣＥＡ-특이적인 세포독성 Ｔ세포를 생성하는 재조합 아데노바이러스 ＡｄＶＣＥＡ로 트랜스덕션된 수지상세포, 이를 포함하는 백신 및 약제학적 조성물
EP1748067A1 (en) 2005-07-29 2007-01-31 Institut Pasteur Polynucleotides encoding MHC class I-restricted hTERT epitopes, analogues thereof or polyepitopes
DK1989224T3 (da) 2006-02-24 2011-02-14 Us Gov Health & Human Serv Immunogene peptider og anvendelsesmetoder
US8871211B2 (en) 2006-09-28 2014-10-28 Cedars-Sinai Medical Center Cancer vaccines and vaccination methods
WO2008127285A2 (en) 2006-10-05 2008-10-23 The Board Of Trustees Of The University Of Arkansas Target peptides for ovarian cancer immunotherapy
CA2867976A1 (en) 2009-03-05 2010-09-10 Macrocure, Ltd. Activated leukocyte composition
CN103209682A (zh) * 2010-09-09 2013-07-17 马克罗柯尔有限公司 活化白血球调节上清液以及用于伤口愈合的用途

Also Published As

Publication number Publication date
MX2014010958A (es) 2015-11-18
WO2013136182A1 (en) 2013-09-19
EP2825634A1 (en) 2015-01-21
JP2015516374A (ja) 2015-06-11
CA2865553A1 (en) 2013-09-19
US20150030635A1 (en) 2015-01-29
IN2014DN08093A (2) 2015-05-01

Similar Documents

Publication Publication Date Title
US10851346B2 (en) MTOR/STAT3 signal inhibitor-treated mesenchymal stem cell having immunomodulatory activity, and cell therapy composition comprising same, for preventing or treating immune disorders
Zhang et al. Mesenchymal stem cells alleviate bacteria‐induced liver injury in mice by inducing regulatory dendritic cells
Hodge et al. Overexpression of microRNA-155 enhances the efficacy of dendritic cell vaccine against breast cancer
Lin et al. Chitosan as an adjuvant-like substrate for dendritic cell culture to enhance antitumor effects
TW201341400A (zh) 單核球增殖劑、單核球增殖用培養基、單核球之製造方法、樹突細胞之製造方法、及樹突細胞疫苗之製造方法
CN112779217B (zh) 一种高记忆表型肿瘤浸润t淋巴细胞的培养方法
Bao et al. In situ sprayed exosome-cross-linked gel as artificial lymph nodes for postoperative glioblastoma immunotherapy
CN103432007A (zh) 牙齿相关干细胞的新用途
CN104491853A (zh) 一种人树突状细胞肿瘤疫苗的制备方法
BRPI0809767B1 (pt) Composição para o tratamento do melanoma, composição para o tratamento de melanomas humanos, procedimento para preparação da composição e procedimento para preparar a composição para tratamento de melanomas humanos
Yu et al. Steady state dendritic cells with forced IDO expression induce skin allograft tolerance by upregulation of regulatory T cells
Fleshner et al. A 9L gliosarcoma transplantation model for studying adoptive immunotherapy into the brains of conscious rats
CA3062883A1 (en) Vaccine containing cancer cells inactivated by photodynamic treatment with metal-based coordination complexes, and immunotherapy method using same
JP5303113B2 (ja) 癌ワクチン
CN101626781B (zh) 制备具有抗肿瘤免疫应答反应的细胞群的方法
Rodriguez-Lecompte et al. Cell-based cancer gene therapy: breaking tolerance or inducing autoimmunity?
US20240002798A1 (en) Method for preparing immunogenicity-enhanced cd103+ fcgr3+ dendritic cell by treatment with interleukin-33 and pharmaceutical composition comprising same dendritic cell for cancer immunotherapy
Cui et al. Effective adoptive transfer of haploidentical tumor-specific T cells in B16-melanoma bearing mice
CN105219728A (zh) 一种用于激活乳腺癌特异性免疫反应的试剂盒
RU2267326C2 (ru) Способ иммунотерапии опухолевым лизатом с адъювантом беталейкин больных солидными опухолями
CN105219727A (zh) 一种用于激活结直肠癌特异性免疫反应的试剂盒
AR Aleixo et al. Immunotherapy with dendritic cells as a cancer treatment: perspectives and therapeutic potential
CN105219723A (zh) 一种用于激活胃癌特异性免疫反应的试剂盒
CN105219717A (zh) 一种一型极化树突状细胞及其诱导方法和应用
Bora et al. Efficacious Dendritic Cell Based Immunotherapy for Advanced Solid Tumors: Three Case Studies. Medical & Clinical Research 6 (4): 495-503

Legal Events

Date Code Title Description
FA93 Acknowledgement of application withdrawn (no request for examination)

Effective date: 20160314